No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / ...
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations ...
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supportersProceeds to ...
Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...
Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biology * Lead progra ...
Comparative trials are among the hardest studies to execute in medtech, especially when the control arm is a long-established ...
UR Medicine Finger Lakes Health is recognizing and celebrating 11 outstanding nurses for excelling in their professional ...
Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an accep ...
Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...
With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trialsNEW YORK, Dec.
Sagimet Biosciences Inc. stock rated Strong Buy on promising drug data and pipeline growth in acne and MASH. Click for this ...
GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback